Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
67.49
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
August 26, 2022
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with...
Via
Benzinga
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance
August 02, 2022
Via
Benzinga
Recap: Incyte Q2 Earnings
August 02, 2022
Incyte (NASDAQ:INCY) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings for Incyte
July 28, 2022
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
10 Most Oversold Stocks To Buy In August 2022
August 10, 2022
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
August 02, 2022
Jakafi sales beat and the company raised its guidance. But another drug fell short.
Via
Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From
Incyte
Via
Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
New Indication Approval For Incyte "To Usher New Growth Avenue"
July 21, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
July 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte to Report Second Quarter Financial Results
July 12, 2022
From
Incyte
Via
Business Wire
Twitter And 3 Other Stocks Insiders Are Selling
July 12, 2022
US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
July 11, 2022
Four pharmaceutical stocks, including three biotech movers, are making big moves.
Via
Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
7 Defensive Stocks to Buy for a Bear Market
June 27, 2022
As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market.
Via
InvestorPlace
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
June 14, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
June 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
June 14, 2022
CNBC
Via
Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
June 14, 2022
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.
Via
Benzinga
Insights On Incyte Corporation
June 04, 2022
In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million...
Via
Talk Markets
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.